NVS Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 3.97%, SMA50 11.52%, SMA200 27.9%). The stock’s 14-day RSI is 70.7 (overbought), while the ATR of 2.64 points to moderate volatility. The stock remains sitting in the mid-range of its 52-week band, trading -1.49% below its high and over 69.38% above its low. Average 10-day trading volume of 2.54 million shares is slightly above the 3-month average of 1.72 million, indicating heightened recent market interest.

Novartis AG generated EPS of $7.19 over the past year. Five-year average earnings growth is 15.38%. Wall Street analysts project EPS growth of 6.19% annually over the next five years. The latest quarter delivered EPS of $1.99. The next quarter is forecast at $2.11. Next year's EPS is expected at $8.35. Analyst sentiment is bearish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $170.00 to $118.00. The high target offers 6.32% upside. The low target suggests -26.2% downside. The mean target is $144.00. This offers -9.94% upside. Novartis AG earnings surprise history is a mixed track record. The quarter that ended April 28, 2026, missed forecasts by -5.69%. The prior quarter beat by 2.01%. Over the last six quarters, Apple has recorded several small beats. These include 10.0% in January 31, 2025.

Novartis AG has 1.94 billion shares outstanding. The public float is 1.84 billion shares, elevated short interest at 0.21% of float. This equals 3.97 million shares. The short ratio is 2.01 days. Institutional investors hold 7.05% of the float. Insiders own 0.0%.

Novartis AG last paid a dividend of 4.74 per share, this equals a trailing yield of roughly 3.37%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $207.72. This means the shares are trading below this model’s fair value.

Novartis AG trades at a P/E ratio of 22.78, slightly below the S&P 500 average, with a price-to-sales ratio of 5.44 and a price-to-book ratio of 7.93 trading at moderately above to book value. The P/FCF stands at 18.65, also above market averages.

Novartis AG (NYSE:NVS) closed at $159.90 USD, gaining $5.76 (3.74%) from the previous close of $154.14. The stock is currently mid-range between its 52-week high and low $112.34 and $170.46. With a market capitalization of about $305.10 billion, Novartis AG is classified as a mega-cap and shows lower-than-market volatility (beta ~0.49). Key stats such as the average daily volume over the past year has been around 1.71 million shares, in line with its 52-week average. Headquartered in Basel, BS, Novartis AG operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Vas Narasimhan, the company employs approximately 75,511 people and listed since November 07, 1996. Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products.

Our AI price prediction model suggests that Novartis AG stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.93%, with price expected at $164.59 by July 16, 2026, within a range of $162.10 to $167.16 3-Month Outlook: Projected fall of -1.89%, reaching $156.87 by September 30, 2026, with a range of $150.84 to $162.07. 1-Year Outlook: Projected gain of 8.4%, with price at $173.33 by July 02, 2027, within a range of $170.01 to $177.06.

Novartis AG (NYSE:NVS) shares are flat 4.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Novartis AG trading at a premium to the broader market with a P/E of 22.78. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $121.44, suggesting -24.05% downside. Our AI forecast model points to short-term strength (2.93% over two weeks), a medium-term fall (-1.89% over three months), and a longer-term gain (8.4% over one year), with expected trading ranges indicating moderate volatility.